Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: Might c-KIT represent a therapeutic target?

Veterinary Immunology and Immunopathology

Volumn 152, Issue 3-4, 2013, Pages 325-332

  Giantin, M ^a   Aresu, L ^a   Arico A ^a   Gelain, M E ^a   Riondato, F ^b   Martini, V ^c   Comazzi, S ^c   Dacasto, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute leukemia; C KIT; Chronic lymphocytic leukemia; Dog; Tyrosine kinase inhibitors

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; STEM CELL FACTOR RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA SEQUENCE; DOG DISEASE; EXON; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE MUTATION; IMMUNOCYTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UNDIFFERENTIATED CARCINOMA;

ANIMALS; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; DOG DISEASES; DOGS; EXONS; FEMALE; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RNA, MESSENGER; RNA, NEOPLASM;

CANIS FAMILIARIS;

EID: 84875538090     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2013.01.003     Document Type: Article

References (35)

1. Adam F., Villiers E., Watson S., Coyne K., Blackwood L. Clinical pathological and epidemiological assessment of morphologically and immunologically confirmed canine leukaemia. Vet. Comp. Oncol. 2009, 3:181-195.
2. Advani A.S. Targeting the c-kit receptor in the treatment of acute myelogenous leucemia. Curr. Hematol. Malig. Rep. 2006, 1:101-107.
3. Advani A.S., Rodriguez C., Jin T., Jawde R.A., Saber W., Baz R., Kalaycio M., Sobecks R., Sekeres M., Tripp B., His E. Increased c-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk. Res. 2008, 32:913-918.
4. Amrein P.C. The potential for dasatinib in treating chronic lymphocytic leukaemia, acute myeloid leukaemia, and myeloproliferative neoplasms. Leuk. Lymphoma 2011, 52(5):754-763.
5. Beghini A., Ripamonti C.B., Cairoli R., Cazzaniga G., Colapietro P., Elice F., Nadali G., Grillo G., Haas O.A., Biondi A., Morra E., Larizza L. KIT activating mutations: incidence in adult and pediiatric acute myeloid leucemia, and identification of an internal tandem duplication. Haematologica 2004, 89:920-925.
6. Bene M.C., Bernier M., Casanovas R.O., Castaldi G., Knapp W., Lanza F., Ludwig W.D., Matutes E., Orfao A., Sperling C., van't Veer M.B. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. Blood 1998, 92:596-599.
7. Breen M., Modiano J.F. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans - man and his best friend share more than companionship. Chromosome Res. 2008, 16:145-154.
8. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., Gari M.A., Peake I.R., Löwenberg B., Reilly J.T. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br. J. Haematol. 2005, 121:775-777.
9. Carulli G., Marini A., Baccelli E., Lambelet P., Lari T., Azzarà A. Association of B-chronic lymphocytic leukemia and acute myeloid leukemia. J. Exp. Clin. Cancer Res. 2007, 26:421-424.
10. Comazzi S., Gelain M.E., Martini V., Riondato F., Miniscalco B., Marconato L., Stefanello D., Mortasino M. Immunophenotype predicts survival time in dogs with chronic lymphocitic leukemia. J. Vet. Intern. Med. 2011, 25:100-106.
11. Corbacioglu S., Kilic M., Westhoff M.A., Reinhardt D., Fulda S., Debatin K.M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006, 108:3504-3513.
12. Dunmire V., Wu C., Symmans W.F., Zhang W. Increased yield of total RNA from fine-needle aspirates for use in expression microarray analysis. Biotechniques 2002, 33:890-896.
13. Edling C.E., Hallberg B. c-KIT - a hematopietic cell essential receptor tyrosine kinase. Int. J. Biochem. Cell Biol. 2007, 39:1995-1998.
14. Gelain M.E., Rossi G., Giori L., Comazzi S., Paltrinieri S. Identification of neoplastic cells in blood using the Sysmex XT-2000iV: a preliminary step in the diagnosis of canine leukemia. Vet Clin Pathol. 2010, 39:169-179.
15. Giantin M., Vascellari M., Morello E.M., Capello K., Vercelli A., Granato A., Lopparelli R.M., Nassuato C., Carminato A., Martano M., Mulinelli F., Da casto M. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. J. Vet. Diagn. Invest. 2012, 24:116-126.
16. Goemans B.F., Zwaan C.M., Miller M., Zimmermann M., Harlow A., Meshinchi S., Loonen A.H., Hählen K., Reinhardt D., Creutzig U., Kaspers G.J., Heinrich M.C. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
17. Horny H.P., Sotlar K., Stellmacher F., Valent P., Grabbe J. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J. Clin. Pathol. 2006, 59:264-268.
18. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., Setoguchi A., Ono K., Washizu T., Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J. Vet. Intern. Med. 2008, 22:985-988.
19. Kern W., Kohlmann A., Schoch C., Schnittger S., Haferlach T. Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. Cancer 2006, 107:2401-2407.
20. Leifer C.E., Matus R.E. Lymphoid leukemia in the dog. Acute lymphoblastic leukemia and chronic lymphocytic leukemia. Vet. Clin. North Am. Small Anim. Pract. 1985, 15:723-739.
21. Lennartsson J., Jelacic T., Linnekin D., Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 2005, 23:16-43.
22. -ΔΔCt method. Methods 2001, 25:402-408.
23. London C.A., Hannah A.L., Zadovoskaya R., Chien M.B., Kollias-Baker C., Rosenberg M., Downing S., Post G., Boucher J., Shenoy N., Mendel D.B., McMahon G., Cherrington J.M. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin. Cancer Res. 2003, 9:2755-2768.
24. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., Bergman P.J., Couto G.C., Mauldin G.N., Michels G.M. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer Res. 2009, 15:3856-3865.
25. Masson K., Ronnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell. Signal. 2009, 21:1717-1726.
26. Mizuki M., Ueda S., Matsumura I., Ishiko J., Schwable J., Serve H., Kanakura Y. Oncogenic receptor tyrosine kinase in leukemia. Cell Mol. Biol. (Noisy-le-grand) 2003, 49:907-922.
27. Paietta E., Ferrando A.A., Neuberg D., Bennett J.M., Racevskis J., Lazarus H., Dewald G., Rowe J.M., Wiernik P.H., Tallman M.S., Look A.T. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004, 104:558-560.
28. Ray P., Krishnamoorthy N., Ray A. Emerging functions of c-kit and its ligand stem cell factor in dendritic cells. Cell Cycle 2008, 7:2826-2832.
29. Shimada A., Taki T., Tabuchi K., Tawa A., Horibe K., Tsuchida M., Hanada R., Tsukimoto I., Hayashi Y. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukaemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006, 107:1806-1809.
30. Sperling C., Schwartz S., Buchner T., Thiel E., Ludwig W.D. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica 1997, 82:617-621.
31. Stirewalt D.L., Meshinchi S. Receptor tyrosine kinase alterations in AML - biology and therapy. Cancer Treat. Res. 2010, 145:85-108.
32. Tsao A.S., Kantarjian H., Thomas D., Giles F., Cortes J., Garcia-Manero G., Huh Y., Yang Y., Shen Y., Albitar M., Estey E. C-kit receptor expression in acute leukaemia - association with patient and disease characteristics and with outcome. Leuk. Res. 2004, 28:373-378.
33. Usher S.G., Radford A.D., Villiers E.J., Blackwood L. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Exp. Hematol. 2009, 37:65-77.
34. Valli V.E., Jacobs R.M., Parodi A.L., Vernau W., Moore P.F. Histological Classification of Haematopoietic Tumors of Domestic Animals. World Health Organization, Second Series 2002, vol. III. Armed Forces Institute of Pathology, Washington, DC.
35. Wang Y.Y., Zhou G.B., Yin T., Chen B., Shi J.Y., Liang W.X., Jin X.L., You J.H., Yang G., Shen Z.X., Chen J., Xiong S.M., Chen G.Q., Xu F., Liu Y.W., Chen Z., Chen S.J. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1104-1109.